CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Trophectoderm (TE) Biopsy +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07076719
NCT07076719N/ACompleted

Cell-free DNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for Preimplantation Genetic Diagnosis

Sohag University·observational·Posted Jul 22, 2025·Updated Jul 22, 2025

In Brief

An observational study evaluating Trophectoderm (TE) Biopsy and Non-invasive Preimplantation Genetic Diagnosis for to Evaluate the Feasibility and Accuracy of Using cfDNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for PGD. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study aims to evaluate the feasibility and accuracy of using cfDNA analysis of spent embryo culture media as a non-invasive approach for PGD. Specifically, the objectives of the study are: 1. To collect SCM from blastocysts of good quality obtained from IVF cycles. 2. To extract cfDNA from the collected SCM using a commercially available kit. 3. To assess the chromosomal content in both cfDNA and gDNA samples via array-based comparative genomic hybridization (aCGH). 4. To compare the results obtained using cfDNA analysis to those obtained using conventional invasive PGD methods, such as blastomere biopsy. 5. To evaluate the potential advantages of using cfDNA analysis of spent embryo culture media for PGD, including reduced risk of harm to the embryo, reduced cost, and increased efficiency.

Study Details

Timeline

N/ACompletedFinished
202420252026
First PostedJul 22, 2025
Enrollment StartOct 1, 2023
Primary CompletionAug 28, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11 months ago

Interventions

Trophectoderm (TE) Biopsyother

* Blastocyst Grading: Blastocyst grading was based on criteria that classified embryos as good, fair, or poor using the simplified SART embryo scoring system (Heitmann et al., 2013): * Good: AA or AB. * Fair: BA, BB, BC. * Poor: CB or CC. * Biopsy Criteria: TE biopsy was performed when an embryo had at least one grade B or better for either the ICM or TE on day 5 of development. When no good-quality blastocysts were available in the same cohort, CC grade blastocysts were biopsied. * Biopsy Procedure: 5-8 cells were laser-biopsied from the TE. These cells were then rinsed and tubed for PGT. * Cryopreservation: The biopsied embryo was cryopreserved by vitrification (Ref. 90133, Vit Kit-Freeze, Irvine Scientific, Santa Ana, USA) (Richardson et al., 2015).

Non-invasive Preimplantation Genetic Diagnosisother

* DNA Contamination Minimization: o SCM was harvested after embryo culture with care taken not to include cellular material. * Sample Storage: * Processing for Genetic Analysis: 6\. DNA Extraction and Sample Preparation 7. Microarray Comparative Genomic Hybridization (aCGH) * Chromosomal Assessment: * BAC-chip Slides: * Labeling and Hybridization: * Scanning and Data Acquisition: * Data Processing and Analysis: 8\. Validation and Quality Control * Robust quality control measures included: